Skip to main content

Table 3 Lipid and BP treatment and control rates by CKD stage in US adults ≥20 years of age with CKD Stage 1–4* based on 2001–2010 NHANES participants

From: Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010

Variable No CKD All CKD CKD Stage: P
  (n=8,487) (n=1,428) 1 2 3a 3b 4  
    (n=285) (n=337) (n=545) (n=201) (n=60)  
Lipid treatment and control (%)‡         
  Antihyperlipidemics§ 11.8 (0.5) 30.4 (1.5) 18.1 (2.9) 31.4 (2.4) 33.0 (2.5) 40.4 (4.2) 44.8 (7.1) <0.001
  LDL-C <100 mg/dL ND 40.0 (1.7) 35.8 (3.6) 38.2 (3.6) 38.4 (2.4) 52.8 (3.9) 50.7 (8.5) 0.135
BP treatment and control (%)‡         
  Antihypertensives║ 17.4 (0.6) 54.4 (1.6) 30.2 (3.2) 54.8 (3.7) 62.0 (2.5) 71.3 (3.4) 78.9 (5.8) <0.001
  BP ≤130/80 mmHg ND 44.6 (1.8) 49.5 (4.0) 42.4 (3.7) 41.6 (2.9) 52.3 (4.3) 30.2 (6.2) 0.019
  1. Values are weighted estimates presented as percent (standard error). Estimates were standardized to the July 2008 US census population ≥20 years of age. ND, not determined.
  2. *CKD Stage 1–4 was identified by the presence of kidney damage (based on albuminuria) and level of decline in kidney function (based on eGFR), and staged using modified National Kidney Foundation criteria (see Methods).
  3. P values are for Stage 1 versus Stage 4 CKD, obtained using the SAS procedure SURVEYLOGISTIC; P values for No CKD versus All CKD are all <0.001, obtained using the SAS procedure SURVEYFREQ (see Methods).
  4. ‡All drug utilization was self-reported.
  5. §Any lipid-lowering agents including statins, fibric acid derivatives, bile acid sequestrants, cholesterol absorption inhibitors and other antihyperlipidemic agents.
  6. ║Any antihypertensive agents including β-blockers, calcium channel blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and other BP-lowering agents.